Skip to main content
Medicine 3% exam weight

Adherence Metrics

Part of the Saudi GP Board study roadmap. Medicine topic medici-015 of Medicine.

→ See in Roadmap Saudi GP Board Study Plans Build 1-Month Plan
By Last updated 3% exam weight

Adherence Metrics

🟢 Lite — Quick Review (1h–1d)

Rapid summary for last-minute revision before your exam.

Chronic disease management in primary care is the structured, longitudinal follow-up of conditions such as diabetes, hypertension, asthma, and chronic kidney disease (CKD) using a written care plan, scheduled reviews, and patient self-management support.

  • Adherence vs persistence: adherence = correct execution day-to-day; persistence = duration until discontinuation.
  • Core formula: Medication Adherence Rate = (Doses taken as prescribed ÷ Doses prescribed) × 100%.
  • Care plan anchor: every chronic patient needs SMART goals and a documented review interval.
  • Exam yield: expect 2–4 MCQs testing adherence metrics, polypharmacy risk, and referral triggers.

🟡 Standard — Regular Study (2d–2mo)

Standard content for students with a few days to months.

Definition and Scope

Chronic disease management (CDM) is the proactive, organised follow-up of patients with long-term conditions in the family medicine clinic. It combines clinical monitoring, structured education, polypharmacy review, and coordination across primary, secondary, and tertiary services.

Saudi MoH guidance positions the general practitioner (GP) as the coordinator of a multidisciplinary team that includes health educators, pharmacists, and specialist physicians.

Adherence Metrics

Three quantitative measures recur in the Saudi GP Board paper. All three are expressed as a percentage over a defined evaluation period.

MetricFormulaClinical use
Medication Adherence Rate (MAR)(Doses taken as prescribed ÷ Doses prescribed) × 100Pill-count or electronic monitor verification
Possession Ratio (MPR)(Days supplied ÷ Days in period) × 100Pharmacy refill data
Proportion of Days Covered (PDC)(Days covered ÷ Total days in period) × 100Preferred quality metric for chronic regimens

Screening Tools and Care Planning

  • Morisky Medication Adherence Scale (MMAS-8): 8-item screening instrument; a score ≥6 suggests low adherence. Use as adjunct, never as sole diagnostic.
  • SMART goals: Specific, Measurable, Achievable, Relevant, Time-bound objectives documented at each visit.
  • Polypharmacy review: reconcile medications at every visit; apply deprescribing principles for elderly multimorbid patients.

🔴 Extended — Deep Study (3mo+)

Comprehensive coverage for students on a longer study timeline.

High-Yield Differentiations

Examiners exploit subtle distinctions between overlapping concepts. Memorise the contrasts below because they appear in stem-based MCQs.

Concept AvsConcept B
Adherence (daily execution)vsPersistence (time to discontinuation)
MPR (refill-based, can exceed 100%)vsPDC (calendar-based, capped at 100%)
Multimorbidity (≥2 chronic diseases)vsComorbidity (additional index condition)
Patient-centred care (patient values drive decisions)vsShared decision-making (explicit two-way negotiation)

Common Pitfalls

  1. Reporting MPR and PDC as interchangeable when PDC is the Saudi MoH-preferred quality metric and is capped at 100%.
  2. Treating a single MMAS-8 score as diagnostic — the scale is a screening adjunct, not a confirmation tool.
  3. Failing to document a structured care plan with measurable review dates, which exposes the GP to medico-legal risk.
  4. Ignoring polypharmacy in patients ≥65 years, where Beers Criteria and STOPP/START tools apply.
  5. Relying solely on patient-reported adherence without objective refill or biochemical verification.

Worked Example

A 62-year-old male with type 2 diabetes and hypertension collects 90 days of metformin and 90 days of amlodipine over a 180-day evaluation window.

  • PDC for metformin: (90 ÷ 180) × 100 = 50% → below the 80% threshold for adequate chronic-disease adherence.
  • PDC for amlodipine: (90 ÷ 180) × 100 = 50% → same classification.
  • Action: flag as non-adherent, review MMAS-8, simplify regimen (fixed-dose combination), and schedule follow-up within 4 weeks.

Practice Prompts

  1. Calculate PDC for a patient who refilled 120 days of atorvastatin during a 150-day period and justify whether ≥80% adherence is met.
  2. Outline the components of a Saudi MoH-aligned chronic care plan for a newly diagnosed diabetic, including SMART goals and review interval.

Continue your study

Content adapted based on your selected roadmap duration. Switch tiers using the selector above.

Sources & verification